Walgreens has struggled as foot traffic at its stores dwindle and pharmacy business faces slimmer reimbursement rates on prescription drugs.
Walgreens Boots Alliance is suspending its quarterly dividend as the company works to “evaluate and refine its capital allocation policy consistent with the company's broader long-term turnaround efforts.”
Walgreens Boots Alliance has suspended its quarterly cash dividend amid restructuring efforts, the U.S. pharmacy chain operator said on Thursday, sending its shares down nearly 8% in extended trading.
No investor likes it when a potential buyout deal for one of their holdings hits a serious roadblock. This is apparently happening to Walgreens Boots Alliance (WBA -4.46%), according to a media report.
The Wall Street Journal previously reported that Walgreens and Sycamore Partners were discussing a deal that could be finalized early this year.
After a tough year for Walgreens (WBA) investors in 2024, shares may have appeared poised to start 2025 on strong note after the company's first-quarter results topped expectations.
Major U.S. equities indexes advanced as the markets kicked off a shortened trading week following the Martin Luther King Jr. holiday and President Donald Trump's inauguration.
Walgreens Boots Alliance (WBA) shares sank Tuesday, the first day of trading since the Department of Justice (DOJ) on Friday announced a lawsuit accusing the pharmacy chain of dispensing "millions of unlawful prescriptions" that had no legitimate medical purpose.
Shares of Walgreens Boots Alliance (WBA -12.50%) pulled back today after the company again ran into trouble with regulators.
Last week, the U.S. Department of Justice filed a civil complaint against Walgreens Boots Alliance Inc WBA and its subsidiaries, alleging widespread violations of the Controlled Substances Act (CSA) and False Claims Act (FCA).
Walgreens stock tumbled Tuesday after the DOJ said the retail pharmacy violated federal law by filling controlled substance prescriptions. The post Walgreens Reverses 40% Sprint As DOJ Slams Opioid Prescriptions appeared first on Investor's Business Daily.
Walgreens Boots Alliance Inc is set for a hammering when the market reopens on Tuesday after being accused by the government of filling unlawful opioid prescriptions. America's US Justice Department late last week alleged the pharmacy chain had contributed to the opioid epidemic by filling millions of unlawful prescriptions.